RT @ShimaghavimiMD: #EGFR activation limits the response of #livercancer to #lenvatinib https://t.co/ya4thwHXuj
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
CRISPR screens identify liver cancer synthetic lethality -> combo clinical trial identifies “a promising strategy for the approximately 50% of patients with advanced HCC who have high levels of EGFR”. Functional genomics strikes again https://t.co/aDAN
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @lisadwane: The power of CRISPR screens 🙌 https://t.co/1H9dLXM5ml
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
#EGFR activation limits the response of #livercancer to #lenvatinib https://t.co/ya4thwHXuj
The power of CRISPR screens 🙌
#EGFR activation limits the response of #livercancer to #lenvatinib https://t.co/prmlfMEc0j
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical trial shows proof-of-concept in previously treatment-resistant folks, identifying a new therapy for ~50% of liver cancers. Incredibly impr
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/vwglEpCHw4
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
เตรียมรอดู Lenvatinib + Gefitinib https://t.co/6KgzSmYLx5
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
Nice to know - to get a Nature paper on cancer drug resistance/combination targeted therapies, all we need to do is our normal in vitro stuff & add CRISPR & add a mouse study.............. and a clinical trial!😱😅@kathygately1 @MartinBarr10 https:
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/FNSGynScPU
Congratulations to Rene Bernards and the entire team behind "EGFR activation limits the response of liver cancer to lenvatinib", out today in @Nature. A fantastic blueprint/path from basic #cancer #science to clinical trials. 👍 https://t.co/uC2OX2DKe8
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
Another step in the direction of precision medicine in HCC. Looking back at @HccTagConf and the movement towards grabbing more tissue to guide therapy.
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/T0zLed3ALV
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
@drlaurarandle
@richlaing
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
EGFR activation limits the response of liver cancer to lenvatinib | Nature https://t.co/w0Tpb8UMGD
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @BernardsLabora1: Today we published in Nature a powerful new drug combination for the treatment of liver cancer. We are grateful to ou…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/1GRwBaQSkw https://t.co/YSBXSNctGd | #research #manuscripts @nature
Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cancer #clinicalresearch https://t.co/Ev0mQfxuG3